Collegium Pharmaceutical, Inc (COLL) — SEC Filings
Collegium Pharmaceutical, Inc (COLL) — 39 SEC filings. Latest: 10-Q (May 7, 2026). Includes 19 8-K, 7 10-Q, 5 SC 13G/A.
View Collegium Pharmaceutical, Inc on SEC EDGAR
Overview
Collegium Pharmaceutical, Inc (COLL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 7, 2026: Collegium Pharmaceutical, Inc. announced on April 2, 2026, a change in its executive team. Specifically, the company reported the departure of certain officers and the election of new directors, as detailed in Item 5.02 of their 8-K filing.
Sentiment Summary
Across 39 filings, the sentiment breakdown is: 3 bullish, 36 neutral. The dominant filing sentiment for Collegium Pharmaceutical, Inc is neutral.
Filing Type Overview
Collegium Pharmaceutical, Inc (COLL) has filed 7 10-Q, 19 8-K, 2 DEFA14A, 2 DEF 14A, 2 10-K, 1 8-K/A, 5 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (39)
Risk Profile
Risk Assessment: Of COLL's 31 recent filings, 0 were flagged as high-risk, 14 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $575.118M |
| Net Income | $45.907M |
| EPS | $1.00 |
| Debt-to-Equity | 4.85 |
| Cash Position | $150.096M |
| Operating Margin | N/A |
| Total Assets | $1,607.328M |
| Total Debt | $1,788.956M |
Key Executives
- Vikram Karnani
- Dr. Andrew K. C. Chang
- Ms. Jennifer L. Mcneal
- Dr. Paul J. Maddon
- Ms. Susan J. Froehlich
- Michael Dean
- Steven Hearne
- Dr. Richard M. Smith
- Dr. Michael L. Smith
- Michael L. Dean
- Dr. Paul J. Clancy
- Michael Miller
- David Rosen
Industry Context
Collegium Pharmaceutical operates in the highly competitive pharmaceutical sector, focusing on specialty branded prescription drug products. The industry is characterized by significant R&D investment, stringent regulatory oversight, patent protection challenges, and ongoing consolidation through mergers and acquisitions. Key trends include the development of novel therapies, the impact of generics, and evolving reimbursement landscapes.
Top Tags
board-of-directors (4) · 10-Q (4) · corporate-governance (4) · Pharmaceuticals (3) · sec-filing (3) · governance (3) · disclosure (3) · proxy-statement (3) · executive-compensation (3) · share-repurchase (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Product revenues, net (Q3 2025) | $209.361M | Increased 31.4% from $159.301M in Q3 2024 |
| Net income (Q3 2025) | $31.507M | Increased 237.5% from $9.335M in Q3 2024 |
| Product revenues, net (9 months 2025) | $575.118M | Increased 27.9% from $449.500M in 9 months 2024 |
| Net income (9 months 2025) | $45.907M | Decreased 18.9% from $56.654M in 9 months 2024 |
| Cash and cash equivalents (Sept 30, 2025) | $150.096M | Increased from $70.565M at Dec 31, 2024 |
| Intangible asset amortization (9 months 2025) | $166.419M | Increased from $109.833M in 9 months 2024 |
| Common Stock shares outstanding (Oct 31, 2025) | 31,610,976 | Reflects current share count |
| Basic EPS (Q3 2025) | $1.00 | Increased from $0.29 in Q3 2024 |
| Q2 2025 Share Repurchases | $10.0M | Amount of common stock repurchased during the three months ended June 30, 2025. |
| Accelerated Share Repurchase Program | $60.0M | Value of the new ASR program initiated on May 9, 2025. |
| ASR Initial Share Delivery | 1,909,000 | Number of shares initially delivered under the ASR program. |
| 2025 Equity Incentive Plan Shares | 2,000,000 | Total shares authorized for issuance under the new 2025 Equity Incentive Plan. |
| Remaining Share Repurchase Authorization | $40.0M | Amount remaining under the 2024-2025 Share Repurchase Program as of June 30, 2025. |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter being reported. |
| Filing Date | 2025-05-08 | The date the 10-Q was officially submitted to the SEC. |
Forward-Looking Statements
- {"claim":"Rubric Capital Management LP will maintain its significant passive stake in Collegium Pharmaceutical, Inc. throughout 2024.","entity":"Rubric Capital Management LP","targetDate":"December 31, 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Collegium Pharmaceutical, Inc (COLL)?
Collegium Pharmaceutical, Inc has 39 recent SEC filings from Jan 2024 to May 2026, including 19 8-K, 7 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of COLL filings?
Across 39 filings, the sentiment breakdown is: 3 bullish, 36 neutral. The dominant sentiment is neutral.
Where can I find Collegium Pharmaceutical, Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Collegium Pharmaceutical, Inc (COLL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Collegium Pharmaceutical, Inc?
Key financial highlights from Collegium Pharmaceutical, Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for COLL?
The investment thesis for COLL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Collegium Pharmaceutical, Inc?
Key executives identified across Collegium Pharmaceutical, Inc's filings include Vikram Karnani, Dr. Andrew K. C. Chang, Ms. Jennifer L. Mcneal, Dr. Paul J. Maddon, Ms. Susan J. Froehlich and 8 others.
What are the main risk factors for Collegium Pharmaceutical, Inc stock?
Of COLL's 31 assessed filings, 0 were flagged high-risk, 14 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Collegium Pharmaceutical, Inc?
Recent forward-looking statements from Collegium Pharmaceutical, Inc include guidance on {"claim":"Rubric Capital Management LP will maintain its significant passive stake in Collegium Pharmaceutical, Inc. thr.